

Price information in local currency for Humira from AbbVie with Adalimumab (ATC: L04AB04), as of February 2022  
in all available package sizes

Country	Trade name	Company	Pack size	Strength	Pharm form	PRP gross	PRP net	PPP	Ex-fact	PRP gross per unit	PRP net per unit	PPP per unit	Ex-fact per unit	Currency	Note
AT	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	546,10	496,46	383,74	360,00	273,05	248,23	191,87	180,00	EUR	reimbursable
BE	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	523,28	493,66	475,69	469,58	261,64	246,83	237,84	234,79	EUR	reimbursable
BG	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen									BGN	not on market
CH	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen									CHF	not on market
CY	Humira	Abbott	2	40 mg in 0,4 ml	Solution for injection prefilled pen									EUR	not on market
CZ	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	17228,07	15661,88	n.a.	14513,61	8614,04	7830,94	n.a.	7256,81	CZK	reimbursable
DE	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	990,03	831,96	799,23	774,14	495,02	415,98	399,61	387,07	EUR	pharmacy discount: 1,77 EUR in favor of the GKV; Manufacturer discount 0,00 EUR
DK	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	9683,45	7746,76	7180,41	6713,68	4841,73	3873,38	3590,20	3356,84	DKK	reimbursable
EE	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	1233,34	1131,50	1126,39	1120,00	616,67	565,75	563,20	560,00	EUR	reimbursable
EL	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen									EUR	not on market
ES	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	1127,57	1084,20	1035,83	1028,29	563,79	542,10	517,92	514,15	EUR	
FI	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	705,82	641,65	550,00	533,50	352,91	320,83	275,00	266,75	EUR	reimbursable
FR	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	557,23	545,77	520,23	487,73	278,61	272,88	260,11	243,87	EUR	reimbursable
HR	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	4607,22	4387,83	4382,07	4038,77	2303,61	2193,92	2191,04	2019,39	HRK	reimbursable
HU	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	275090,00	261990,48	261000,48	250000,46	137545,00	130995,24	130500,24	125000,23	HUF	non-reimbursable
IE	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	n.a.	n.a.	883,77	818,31	n.a.	n.a.	441,89	409,15	EUR	reimbursable
IT	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	1591,60	1446,91	1007,77	964,36	795,80	723,45	503,89	482,18	EUR	non-reimbursable (outpatient sector)
LT	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	885,43	843,27	828,79	823,00	442,72	421,64	414,40	411,50	EUR	reimbursable
LU	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	508,64	493,83	475,69	469,58	254,32	246,91	237,85	234,79	EUR	reimbursable
LV	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	925,28	826,14	820,09	804,01	462,64	413,07	410,05	402,01	EUR	reimbursable
MT	Humira	V.J.Salomone Pharma Limited	2	40 mg in 0,4 ml	Solution for injection prefilled pen									EUR	not on market
NL	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	n.a.	n.a.	700,02	654,52	n.a.	n.a.	350,01	327,26	EUR	reimbursable
NO	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	10600,60	8480,48	8245,36	7750,64	5300,30	4240,24	4122,68	3875,32	NOK	reimbursable
PL	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	n.a.	n.a.	2386,92	2273,25	n.a.	n.a.	1193,46	1136,63	PLN	H; no PRP available
PT	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	797,46	749,32	722,16	710,10	398,73	374,66	361,08	355,05	EUR	non-reimbursable
RO	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	2227,87	2043,92	2008,92	1978,92	1113,94	1021,96	1004,46	989,46	RON	reimbursable
SE	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	6066,29	6066,29	5889,50	5730,48	3033,15	3033,15	2944,75	2865,24	SEK	reimbursable
SI	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	n.a.	n.a.	364,45	359,99	n.a.	n.a.	182,23	180,00	EUR	reimbursable
SK	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	443,27	402,97	381,74	372,64	221,64	201,49	190,87	186,32	EUR	reimbursable
UK	Humira	AbbVie	2	40 mg in 0,4 ml	Solution for injection prefilled pen	n.a.	n.a.	704,28	616,25	n.a.	n.a.	352,14	308,12	GBP	reimbursable

Sources: national databases; data gathering and calculation by GÖG in the framework of the PPI (Pharma Price Information) service

NL, SI and UK: Due to performance based pharmacy remuneration the PRP is not known in these countries.

CZ: Due to the remuneration scheme for distribution actors there is no common country wide PPP in these countries.

DK, FI, NL, SE and UK: Pls. note that in these countries the manufacturer price is computed via average wholesale mark-ups/margins therefore slight deviations may occur.

AT: Only private customers (who account for approx. 30% of pharmacy sales) pay the PRP, the sickness funds (which account for 70% of pharmacy sales) pay a significantly lower price, the so-called reimbursement price ("Kassenpreis").

HR: Pharmacy remuneration equals a dispensing fee based on the assumption of 1 pack of that medicine on the prescription

IE: For reimbursable products no pharmacy markup is added to the PPP, however, a dispensing fee is applied by the pharmacy.

**Legend:**

PRP gross	pharmacy retail price incl. VAT (discounts, clawbacks, etc. are not accounted for)
PRP net	pharmacy retail price excl. VAT (discounts, clawbacks, etc. are not accounted for)
PPP	pharmacy purchasing price without VAT (discounts, clawbacks, etc. are not accounted for)
Ex-fact	manufacturer selling price without VAT (discounts, clawbacks, etc. are not accounted for)
Reimb.	reimbursement price for sickness funds ("Kassenpreis")
n.a.	price is not available
H	Product is only or mainly dispensed in a hospital setting
company	Marketing authorisation holder
HSE	Health Service Executive (=national health service)
NHS	National Health Service

**Countries:**

AT	Austria	IE	Ireland
BE	Belgium	IT	Italy
BG	Bulgaria	LT	Lithuania

Humira (Adalimumab)

CH	Switzerland	LU	Luxembourg
CY	Cyprus	LV	Latvia
CZ	Czech Republic	MT	Malta
DE	Germany	NL	Netherlands
DK	Denmark	NO	Norway
EE	Estonia	PL	Poland
EL	Greece	PT	Portugal
ES	Spain	RO	Romania
FI	Finland	SI	Slovenia
FR	France	SK	Slovakia
HR	Croatia	SE	Sweden
HU	Hungary	UK	United Kingdom (England and Wales)